Cite
Berger M, Wortmann L, Buchgraber P, et al. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. J Med Chem. 2021;64(17):12723-12737doi: 10.1021/acs.jmedchem.1c00762.
Berger, M., Wortmann, L., Buchgraber, P., Lücking, U., Zitzmann-Kolbe, S., Wengner, A. M., Bader, B., Bömer, U., Briem, H., Eis, K., Rehwinkel, H., Bartels, F., Moosmayer, D., Eberspächer, U., Lienau, P., Hammer, S., Schatz, C. A., Wang, Q., Wang, Q., Mumberg, D., Nising, C. F., & Siemeister, G. (2021). BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. Journal of medicinal chemistry, 64(17), 12723-12737. https://doi.org/10.1021/acs.jmedchem.1c00762
Berger, Markus, et al. "BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies." Journal of medicinal chemistry vol. 64,17 (2021): 12723-12737. doi: https://doi.org/10.1021/acs.jmedchem.1c00762
Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K, Rehwinkel H, Bartels F, Moosmayer D, Eberspächer U, Lienau P, Hammer S, Schatz CA, Wang Q, Wang Q, Mumberg D, Nising CF, Siemeister G. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. J Med Chem. 2021 Sep 09;64(17):12723-12737. doi: 10.1021/acs.jmedchem.1c00762. Epub 2021 Aug 24. PMID: 34428039.
Copy
Download .nbib